Phage Therapy for Staph Infection
(PHAGE-2024-01 Trial)

Recruiting in Palo Alto (17 mi)

Age: Any Age

Sex: Male

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: University of Calgary

No Placebo Group

Trial Summary

What is the purpose of this trial?This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage cocktail to treat and prevent the recurrence of a methicillin-susceptible Staphylococcus aureus prosthetic joint infection of the hip. The patient has exhausted all conventional therapies, both surgical and medical, at considerable detriment to his quality of life. The treatment involves a one time, intra-operative injection of bacteriophages into the joint and 14 days of intravenous phage therapy. The goal is to eliminate the infection and prevent further complications, providing a potential new treatment avenue for patients with difficult-to-treat infections.

Eligibility Criteria

This trial is for someone with a chronic hip joint infection caused by methicillin-sensitive Staphylococcus aureus, who has tried multiple antibiotics and surgeries without success. The bacteria causing their infection must respond to bacteriophage therapy in lab tests.

Inclusion Criteria

I have an ongoing infection in my artificial joint.

The bacteria causing my infection can be treated with bacteriophage therapy.

I've had several unsuccessful antibiotic treatments and surgeries.

Participant Groups

The study is testing a one-time injection of a bacteriophage cocktail directly into the infected hip joint during surgery, followed by two weeks of intravenous phage therapy. It aims to clear the infection and prevent it from coming back.

1Treatment groups

Experimental Treatment

Group I: Open Label ArmExperimental Treatment1 Intervention

Bacteriophage cocktail